Piper Sandler Initiates Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $115
Ultragenyx Pharma Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $115
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Revenues Are Not Doing Enough For Some Investors
2024 Wilson Disease Pipeline Market Analysis Report Featuring Alexion Pharmaceuticals, Inc., Vivet Therapeutics SAS, Ultragenyx Pharmaceutical and Nobelpharma
Morgan Stanley Initiates Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $64
Ultragenyx Pharmaceutical(RARE.US) Officer Sells US$4.15 Million in Common Stock
$Ultragenyx Pharmaceutical(RARE.US)$ Officer KAKKIS EMIL D sold 98,434 shares of common stock on Feb 28, Mar 3, 2025 at an average price of $42.2 for a total value of $4.15 million.Source:
Cantor Fitzgerald Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $118
Ultragenyx to Participate at Investor Conferences in March
Analysts Offer Insights on Healthcare Companies: Icon (ICLR), Pediatrix Medical Group (MD) and Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical | 10-K: FY2024 Annual Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $95
Optimistic Outlook for Ultragenyx Pharmaceutical Amid Promising Gene Therapy Developments
Express News | Ultragenyx Pharmaceutical Shares up 1.7% as FDA Accepts Genetic Disorder Therapy for Review
Express News | Ultragenyx Pharmaceutical Inc - FDA Not Planning Advisory Committee Meeting for Ultragenyx Bla
Express News | Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (Bla) for Ux111 Aav Gene Therapy to Treat Sanfilippo Syndrome Type a (Mps Iiia)
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
CCORF Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $136